

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
12 January 2023 (12.01.2023)



(10) International Publication Number  
**WO 2023/281271 A1**

(51) International Patent Classification:

C07D 401/06 (2006.01) A61P 9/10 (2006.01)  
C07D 403/06 (2006.01) A61P 13/12 (2006.01)  
C07D 413/06 (2006.01) A61P 37/00 (2006.01)  
C07D 417/06 (2006.01) A61P 11/00 (2006.01)  
C07D 409/06 (2006.01) A61K 31/4178 (2006.01)

(21) International Application Number:

PCT/GB2022/051760

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2109946.0 09 July 2021 (09.07.2021) GB  
2202664.5 25 February 2022 (25.02.2022) GB

(71) Applicant: **VICORE PHARMA AB** [SE/SE]; Kornhamn-  
storg 53, SE-111 27 Stockholm (SE).

(72) Inventors: **PETERSEN, Nadia Nasser**; Råbyvägen 19,  
Igh 1403, SE 75422 Uppsala (SE). **HALLBERG, Anders**;  
Kyrkogårdsgatan 27, SE 753 12 Uppsala (SE). **LARHED,**  
**Mats**; Läbygatan 17, SE 752 39 Uppsala (SE). **FEX,**  
**Tomas**; Emeriti Bio, AZ BioVenture Hub, SE-43183 Möl-  
ndal (SE). **OHLSSON, Bengt**; Emeriti Bio, AZ BioVenture  
Hub, SE-43183 Mölndal (SE).

(74) Agent: **POTTER CLARKSON**; The Belgrave Centre,  
Talbot Street, Nottingham Nottinghamshire NG1 5GG  
(GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,


RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NEW SELECTIVE ANGIOTENSIN II COMPOUNDS



(57) Abstract: There is provided pharmaceutical compounds of formula I, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

WO 2023/281271 A1